Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors

Rationale: Breast cancer patients are increasingly treated with neoadjuvant chemotherapy for various reasons. These women receive chemotherapy before any surgery is performed. Many of these tumors need preoperative seed localization to help guide the surgeons to the site of the tumor within the breast. In many hospitals, a radioactive I-125 seed is used for this purpose, which has several disadvantages, such as a slight increase in radiation dose and extensive administrative regulations to monitor the location of the seed at any time (required by law). This administrative work is time consuming, elaborate and prone to errors. Therefore, interest is shifting towards to use of non-radioactive seeds, such as the magnetic seeds used in this study. A drawback of these seeds is the fact that they cause large susceptibility artifacts on (magnetic!) MRI of the breast. Breast MRI is the most accurate modality to monitor response to therapy of these women. CEM, an emerging breast imaging technique, has shown to achieve comparable results with regard to response monitoring but uses no magnetic fields. Hence, CEM might be an attractive alternative response monitoring tool in patients treated with neoadjuvant chemotherapy and having a magnetic seed a surgical marker. To this point, however, no study in humans has confirmed that this is indeed the case.

Objective: To test whether the use of magnetic localization seeds causes image artifacts on CEM.

Study design: Observational feasibility study. Study population: Women (>18 years) able to provide written informed consent and recently diagnosed with (non-palpable) breast cancer or ductal carcinoma in situ (DCIS), who are primarily treated with surgery.

Intervention (if applicable): Image-guided placement of a magnetic seed (Sirius Pintuition) prior to surgery, including control imaging to confirm the correct location of the seed relative to the breast abnormality. In usual patient care this is performed with full-field digital mammography (FFDM), but in this study this control image will be performed with the system in 'contrast-enhanced mammography' or CEM mode, but without using intravenous administration of iodinated contrast agent because the purpose is not repetition of diagnostic imaging, but to rule out any artifacts caused by the seed on CEM. The investigators estimate to include twenty patients to confidently test the hypothesis that magnetic seeds do not cause disturbing artifacts on CEM examinations.

Main study parameters/endpoints: The primary study aim will be to test whether the magnetic seeds caused any disturbing artifacts on CEM images. For this purpose, two radiologists will score the images for the presence of any artifacts and if present, if these are to such an extent that they would hamper diagnostic evaluation of the images. The radiologists will assess the images independently first, and consensus opinion is formed should any discrepancies occur in their judgement. As secondary study, the investigators will document technical success rate of seed deployment and retrieval during surgery, including the assessment of the surgical margins (positive or negative).

Nature and extent of the burden and risks associated with participation, benefit, and group relatedness: The burden and risk for participating subjects are very small. In regular care, a radioactive I-125 seed is placed in the breasts of these women, checking the position with (conventional) FFDM. For this purpose, the iodine seed is replaced with a (radioactive-free) magnetic seed (Sirius Pintuition). The latter did not show any relevant imaging artifacts prior to this study in imaging phantoms (i.e., chicken breasts containing magnetic seeds). Therefore, the investigators feel confident that these seeds will not show artifacts on clinical CEM image, but this needs to be confirmed before additional studies regarding the clinical application of CEM and magnetic seeds combined can be safely performed. The only additional disadvantage for participants is the slight increased radiation dose of the (extra) high-energy image CEM image, which is an increased radiation dose to the breasts of 50-80%. However, these women are all diagnosed with breast cancer requiring adjuvant radiotherapy, which uses radiation doses much, much higher than a single mammographic exposure.

Inclusion criteria

• Included are non-pregnant women (>18 years of age),
• Recently diagnosed with non-palpable invasive breast cancer or DCIS, requiring primary surgical treatment.
• Only women able to provide written informed consent will be considered for this study.

Exclusion criteria

• Excluded are women not meeting the inclusion criteria.